<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BBC34A7B-0627-4FA5-A186-05812A8B46E2"><gtr:id>BBC34A7B-0627-4FA5-A186-05812A8B46E2</gtr:id><gtr:name>Stuttgart University</gtr:name><gtr:address><gtr:line1>Postfach 10 60 37</gtr:line1><gtr:postCode>D-70049</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DCA7B7A-0111-4A7C-95CC-DEAD58B89132"><gtr:id>6DCA7B7A-0111-4A7C-95CC-DEAD58B89132</gtr:id><gtr:name>University of Stockholm</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BBC34A7B-0627-4FA5-A186-05812A8B46E2"><gtr:id>BBC34A7B-0627-4FA5-A186-05812A8B46E2</gtr:id><gtr:name>Stuttgart University</gtr:name><gtr:address><gtr:line1>Postfach 10 60 37</gtr:line1><gtr:postCode>D-70049</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DCA7B7A-0111-4A7C-95CC-DEAD58B89132"><gtr:id>6DCA7B7A-0111-4A7C-95CC-DEAD58B89132</gtr:id><gtr:name>University of Stockholm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/070EB2E9-82F4-41CA-98D4-32F7A9CC0234"><gtr:id>070EB2E9-82F4-41CA-98D4-32F7A9CC0234</gtr:id><gtr:firstName>Gareth</gtr:firstName><gtr:surname>Veal</gtr:surname><gtr:orcidId>0000-0002-1897-8678</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0DA3D420-5600-46F7-8F2C-0EFEE6EF26BD"><gtr:id>0DA3D420-5600-46F7-8F2C-0EFEE6EF26BD</gtr:id><gtr:firstName>Olaf</gtr:firstName><gtr:surname>Heidenreich</gtr:surname><gtr:orcidId>0000-0001-5404-6483</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/425DB6A4-BF09-4A5A-8F3A-3575BD1DC2BA"><gtr:id>425DB6A4-BF09-4A5A-8F3A-3575BD1DC2BA</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Bailey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70BB68F8-BE13-4740-BD7C-0ED5F650CD1A"><gtr:id>70BB68F8-BE13-4740-BD7C-0ED5F650CD1A</gtr:id><gtr:firstName>Roland</gtr:firstName><gtr:surname>Kontermann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57325399-7299-46CD-A73A-6EAD13DDDDDA"><gtr:id>57325399-7299-46CD-A73A-6EAD13DDDDDA</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>Hunter</gtr:otherNames><gtr:surname>Jackson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802495"><gtr:id>3CA9CE98-CAC0-4248-8FFB-E92A7FE5A923</gtr:id><gtr:title>In vivo targeting leukaemic fusion genes with siRNAs</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802495</gtr:grantReference><gtr:abstractText>A research team based at Newcastle University working with a co-investigator at the University of Stuttgart aim to develop a non-toxic therapeutic drug to treat a specific type of leukaemia prevalent in children. Leukaemia occurs due to a genetic change (mutation) within the DNA of bone marrow cells. This results in a mutant RNA transcript which produces an improperly functioning protein. The result is failure of the normal control mechanism for cell development and the uncontrolled growth of white blood cells. The current treatment is chemotherapy with highly toxic and non-specific drugs. Chemotherapy can affect all cells in the body leading to side effects ranging from general ill health during treatment but also, often life-threatening long term damage to organs and unfortunatly imparement or even loss of fertility. The proposed novel therapeutic approach comprises a tiny particle which specifically recognises and attaches to leukaemic cells and then delivers a unique genetic component (so-called short interfering RNAs or siRNAs) into the leukaemic cell. This siRNA adds a second degree of specificity as it recognises and binds only to the unique mutant RNA in the leukaemic cells. This prevents production of the mutant protein and so stops the aberant excessive cell division characteristic of the disease. The particle itself is a mix of fats and protein combined with the siRNA, so the therapy is non toxic to normal cells but lethal to leukaemic cells.</gtr:abstractText><gtr:technicalSummary>Fusion oncogenes and their encoded products provide ideal targets for leukaemia-specific therapeutic strategies because of their exclusive expression in leukaemic cells. However, the majority of these fusion proteins are transcription factors, which are difficult to target with conventional small molecule-based approaches. Using RNA interference (RNAi) with small inhibitory RNA (siRNA), we have demonstrated that several fusion proteins are indispensable for the maintenance of leukaemic growth both in vitro and in vivo. We propose a therapy based on a targeted siRNA delivery system which provides a highly selective approach towards the transformed cells but will not affect healthy haematological cells. We have developed antibody-conjugated nanoparticles which efficiently deliver siRNAs to leukaemic cells subsequently causing a knock-down of the targeted fusion gene. This has been demonstrated as a potential target specific siRNA therapy for Acute Myeloid Leukaemia (AML) in cell culture and murine transplantation models. In the proposed project, we will determine if this Antibody Targeted Nanoparticle (AnTaNa) approach overcomes the problem of delivering sufficient siRNA to be therapeutically effective by assessing the in vivo efficacy, toxicity, pharmacokinetics and -dynamics in murine xenotransplantation models. A specific and efficient antileukaemic effect in these model systems would provide a strong impetus for progressing to clinical studies.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>683809</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Self-organising micelles for siRNA delivery</gtr:description><gtr:id>B4875A78-A11D-45E0-9A37-103EE9F43285</gtr:id><gtr:impact>Successful EPSRC KTA application
Successful EPSRC MRes/PhD application
Multidisciplinary collaboration between polymer chemistry and molecular oncology</gtr:impact><gtr:outcomeId>L8VU3XhPbWs-1</gtr:outcomeId><gtr:partnerContribution>new composite polymers for delivery of siRNAs</gtr:partnerContribution><gtr:piContribution>Strategic design of polymeric micelles, physicochemical characterisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stuttgart</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Cell Biology and Immunology</gtr:department><gtr:description>targeted siRNA delivery</gtr:description><gtr:id>E9EE3D91-5DF8-4368-9EDC-F1411495C8CC</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>KQ136Q2R7yH-1</gtr:outcomeId><gtr:partnerContribution>Knowledge and know how of nanoparticle and scFv production</gtr:partnerContribution><gtr:piContribution>Provision of siRNA, cell and animal models; development of detection method</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Peptide-mediated siRNA delivery</gtr:description><gtr:id>04040ACB-1A92-4A68-9BA6-B28E5B01D183</gtr:id><gtr:impact>BSc thesis at Nijmegen University
Manuscript in preparation
Multidisciplinary approach between peptide chemistry (Stockholm), cell biology (Nijmegen) and molecular oncology (Newcastle)</gtr:impact><gtr:outcomeId>m2aXCDnV9mt-1</gtr:outcomeId><gtr:partnerContribution>New delivery approach providing its implementation into the currently pursued strategy.Provision of new CPPs</gtr:partnerContribution><gtr:piContribution>Physicochemical characterisation of CPPs and their in vitro and in vivo testing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stockholm University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Neurochemistry</gtr:department><gtr:description>Peptide-mediated siRNA delivery</gtr:description><gtr:id>D4FB05E2-3D79-4418-B438-79875C47DA2A</gtr:id><gtr:impact>BSc thesis at Nijmegen University
Manuscript in preparation
Multidisciplinary approach between peptide chemistry (Stockholm), cell biology (Nijmegen) and molecular oncology (Newcastle)</gtr:impact><gtr:outcomeId>m2aXCDnV9mt-2</gtr:outcomeId><gtr:partnerContribution>New delivery approach providing its implementation into the currently pursued strategy.Provision of new CPPs</gtr:partnerContribution><gtr:piContribution>Physicochemical characterisation of CPPs and their in vitro and in vivo testing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>71000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC MRes/PhD</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>0792F2CA-BF08-4785-9CAC-C2394ECBF486</gtr:id><gtr:outcomeId>Htas6bnshF70</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46410</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A polymer nanoparticle platform for siRNA-based therapies for Leukaemia</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>JAG/ML/0612</gtr:fundingRef><gtr:id>5EA8ACE4-47FE-42D1-802E-EF2EB7A56DAF</gtr:id><gtr:outcomeId>aYAqKuFntoP</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC KTA</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>00DC2081-EF37-4352-A2EB-A10C7865B2AF</gtr:id><gtr:outcomeId>G5Pq9tKdyQr0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Particle formulations used to targeted delivery of siRNAs in leukaemia</gtr:description><gtr:id>C2C88EAC-0EF2-41A7-8C89-E7FDF533B66D</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>KMX7XRsyZts</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Nanoparticles</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>253B735B-AC56-4AAD-BBD9-801705BF38FE</gtr:id><gtr:title>Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a0658f5240ec078dd6ad1aea6430363"><gtr:id>2a0658f5240ec078dd6ad1aea6430363</gtr:id><gtr:otherNames>van Asbeck AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>pm_15159_29_23600610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EB92222-F5BF-4C56-97BF-C423EB301837</gtr:id><gtr:title>Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f157cd64120891bb5e98e9479dfb7a3"><gtr:id>5f157cd64120891bb5e98e9479dfb7a3</gtr:id><gtr:otherNames>Omedes Pujol M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_15159_013_10_013</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802495</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>